DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
SRTS logo

Sensus Healthcare, Inc. Stock Price

NasdaqCM:SRTS Community·US$51.9m Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 115 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SRTS Share Price Performance

US$0
-3.15 (-100.00%)
​
US$5.75
Fair Value
US$0
-3.15 (-100.00%)
​
Price US$0
Mon, 22 Jun 26
Fair ValueUS$5.75
Share Pricen/a

SRTS Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$5.75 45.6% undervalued intrinsic discount

Increased CMS Reimbursement And International Expansion Will Unlock Demand

2users have liked this narrative
0users have commented on this narrative
39users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$6.5 51.8% undervalued intrinsic discount

Growing Global Aging Will Expand Noninvasive Treatment Markets

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$4.5 30.4% undervalued intrinsic discount

US Regulations Will Curtail Sales Yet Unveil Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
SRTS logo
Sensus Healthcare
76.7% undervalued intrinsic discount

SRTS Market Outlook

View narrative
NA
NateF
Published 4 Jan 2025
Read Narrative
SRTS logo
Sensus Healthcare
51.8% undervalued intrinsic discount

Growing Global Aging Will Expand Noninvasive Treatment Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 6 Jul
Read Narrative
SRTS logo
Sensus Healthcare
45.6% undervalued intrinsic discount

Increased CMS Reimbursement And International Expansion Will Unlock Demand

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 22 Jun
Read Narrative
SRTS logo
Sensus Healthcare
30.4% undervalued intrinsic discount

US Regulations Will Curtail Sales Yet Unveil Opportunities

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 4 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

NA
SRTS logo

SRTS Market Outlook

Fair Value: US$13.42 76.7% undervalued intrinsic discount
44 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
SRTS logo

SRTS: 2026 Reimbursement Shift Will Drive Upside Despite Softer Assumptions

Fair Value: US$6.5 51.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
SRTS logo

SRTS: Future Upside Will Hinge On 2026 Margin Recovery

Fair Value: US$5.75 45.6% undervalued intrinsic discount
39 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with limited growth.

1 Risk
1 Reward
View Full Analysis

Sensus Healthcare, Inc. Key Details

US$17.5m

Revenue

US$11.1m

Cost of Revenue

US$6.4m

Gross Profit

US$21.9m

Other Expenses

-US$15.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.94
36.39%
-88.45%
0%
View Full Analysis

About SRTS

Founded
2010
Employees
60
CEO
Joseph Sardano
WebsiteView website
sensushealthcare.com

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.

Recent SRTS News & Updates

Analysis Article • Aug 22

We Think Sensus Healthcare (NASDAQ:SRTS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent updates

No updates

Sensus Healthcare, Inc. Competitors

AGPU logo

Axe Compute

Symbol: NasdaqCM:AGPU
Market cap: US$129.5m
STXS logo

Stereotaxis

Symbol: NYSEAM:STXS
Market cap: US$129.3m
HCAT logo

Health Catalyst

Symbol: NasdaqGS:HCAT
Market cap: US$127.9m
STEX logo

Streamex

Symbol: NasdaqCM:STEX
Market cap: US$122.6m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide